Home >Documents >CURRICULUM VITAE - umfcd.ro · PDF fileAnaliza cazurilor de tuberculoza pulmonara cronica...

CURRICULUM VITAE - umfcd.ro · PDF fileAnaliza cazurilor de tuberculoza pulmonara cronica...

Date post:04-Sep-2019
Category:
View:5 times
Download:0 times
Share this document with a friend
Transcript:
  • 1

    CURRICULUM VITAE Date personale

    Nume: Tudorache Prenumele: Voicu Mircea Locul şi data naşterii: 28.10.1953 Naţionalitatea: română Starea civilă: căsătorit, un copil Profesia: medic primar pneumolog Locul de muncă: U.M.F. „Victor Babeş” Catedra de Pneumologie Funcţia: Profesor Universitar Domiciliul stabil: Str. 1 Decembrie nr 90 sc b et 6 ap.24 Telefon: 0040-722619148 E-mail: [email protected] Limbi străine: engleză, franceză Operare calculator: programe sub windows, navigare net Studii

    1972 – liceul Negruţi, Iaşi 1978 – Absolvent al Facultăţii de Medicină din Iaşi 1985 – medic specialist pneumolog 1991 – medic primar pneumolog 1982 – asistent universitar la disciplina de pneumologie UMF Victor Babeş 1992 – Şef de lucrări UMF Victor Babeş 1994 – Doctor în Medicină cu teza “Contribuţii la cercetarea răspunsului imun în tuberculoza pulmonară” 1995 – Conferenţiar Universitar UMF Victor Babeş 1999 – Profesor Universitar (Șef Clinică) UMF Victor Babeş, Spitalul Clinic de Boli Infecţioase şi Pneumoftiziologie ”Victor Babeş”, Timişoara Calificări postuniversitare 1. Competenţă în eco-abdominal, 1998 2. Competenţă în studii clinice - Fundamentals of clinical trials, Timişoara, Romania, 2005 Membru în asociaţii profesionale 1. Societatea Europeană Respiratorie 2. Societatea Română de Pneumologie 3. Societatea Română de alergologie 4. ACCP (American College of Chest Physicians) 5. Asociația Medicilor Creștini Funcţii deţinute în cadrul asociaţilor profesionale 1. Vicepreşedinte Societăţii Române de Pneumologie, 2002 2. Preşedintele asociaţiei medicilor creştini, 2008

  • 2

    3. Coordonator naţional al grupului de lucru de Reabilitare Pulmonară din cadrul SRP 2007-2012 4. Director la Departamentul XIII de Boli Infecțioase 2011 - prezent Activităţi de cercetare Brevete de invenţie OSIM ”Dispozitiv electronic pentru măsurarea frecvenţei cardiace”. Acordat prin hotărârea nr. 6/107 din 28.08.2009, data eliberării 30.10.2009, nr. 122620 Membru în granturi de cercetare 1. Fiziologia musculaturii netede traheo-bronşice. Studiu experimental şi clinic. Contract cu Ministerul Învăţământului şi al Cercetării. Investigator, 1992 - 1995 2. Bronhomotricitatea: implicaţii imuno-alergice. Contract cu Academia de Ştiinţe Medicale. Investigator. 1992 – 1995 3. Studiul prelimire de revaluare a riscului de îmbolnavire prin TBC la pacienţii HIV/SIDA în tratament şi elaborarea unui protocol prin depistarea cât mai precoce la peroanele infectate HIV. CPSS 2009 iunie – oct. Studii clinice 1. ZYB 30014 – level 2. A multicenter, 26 weeks study to evaluate the Efficacy and Safety of bupropion hydrochloride (SR) phase III (sustained release tablets) for the treatment for nicotine dependence as an aid to smoking. – I was principal investigator. Finalisation date: 23.10.00. 2. FR/95/756/19 A multicenter phase III study, open, comparatively, randomised, within 2 parallel groups, about the Efficacy and Tolerance of cefotaxime in the treatment of acquired community pneumonia, treated in the hospital. I was sub investigator. Duration of study was 6 months. Finalisation date: april 1996. 3. 2003-71-DPI-5 - Development Phase: Title: Double blind, double-dummy, mono-center, randomized, placebo-controlled, crossover study to assess the therapeutic equivalence of Formoterol EasyhalerÒ 12 μg Formoterol / dose versus ForadilÒ Aerolizer 12 μg Formoterol / dose after single- dose application in subjects suffering from COPD Sponsor: HEXAL AG

    4. 2005-33-DOS-2 - Development Phase: Title: A single-dose, randomized, three-period crossover,

    open study to assess the therapeutic bioequivalence of salbutamol from 3 different inhalers

    (Salbutamol 100 μg/dose) in asthmatic subjects Sponsor: HEXAL AG

    5. AVT-01/2/AST/02 - Development Phase: IIa Title: Efficacy and safety of AVT-01 5 mg once

    daily over 7 days in patients with moderate persistent atopic asthma – A double-blind, randomized,

    placebo-controlled clinical study - Sponsor: Avontec GmbH

    6. AVT-01/2/AST/03 - Development Phase: IIa Title: Efficacy and safety of AVT-01 10 mg once

    daily over 7 days in patients with moderate persistent atopic asthma – A double-blind, randomized,

    placebo-controlled clinical study - Sponsor: Avontec GmbH 7. OP-634-001 A Phase III, Randomized, Double –Blind, Multicenter, Paralel Group Study to assess the Efficacy and Safety of Oral Gemifloxacin for the Treatment of Mild to Moderate Community Acquired Pneumonia. I was principal investigator. Finalisation date: 03.25.05. Duration of study was 10 weeks. Sponsor Oscient Pharmaceuticals –USA. 8. RA/PR/3301/011/04 - A 3-month double-blind, double-dummy, randomised, multinational, multicenter, 2-arm parallel-group study comparing the efficacy and safety of formoterol-HFA pMDI 12 ug twice daily and formoterol-DPI 12 ug twice daily, in patients with stable chronic obstructive pulmonary disease., principal investigator. Duration of study 3 months. Aug-Nov 2005. Sponsored by Chiesi Pharmaceutici. SpA Italy.

  • 3

    9. CQAB149B2334 - A 52-week treatment, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to asses the efficacy, safety and tolerability of indacaterol (300 & 600 µg o.d.) in patients with chronic obstructive pulmonary disease, using formoterol (12 µg bid.) as an active control. Sponsor Novartis – Swiss. 10. M/34273/30 A 52-week randomised, double-blind, parallel-group, placebo-controlled, multicentre clinical trial, to assess the efficacy and safety of 200 μg of the anticholinergic LAS 34273 compared to placebo, both administered once-daily by inhalation, in the maintenance treatment of patients with moderate to severe, stable COPD. Duration of study is one year. Allmiral -Spain 11. FLT 3505 An open, randomised ,parallel group multicenter study to compare the efficacy and safety of FlutiForm TM pMDI versus Fluticasone pMDI plus Formoterol DPI in adolescent and adult subjects with mild to moderate servere persistent reversible asthma. Sponsored by Mundipharma USA 2007. 12. CMEX839BDE03 A randomized double-blind , multi-center comparison of efficacy and safety of certoparin ( 3000 U anti-Xaod ) with unfractioned heparin (5000 IU t.i.d.) in the prophylaxis of thromboembolic events in acutely ill medical patients. The study is ongoing. 13. CQMF149B2201 A randomized, multi-center, parallel group, double blind, placebo and formoterol controlled 14 day dose ranging trial of 4 doses of indicaterol delivered via twisthaler in patients with COPD. Sponsored by Novartis. 14. P903-08 A phase multi-center, randomized double blind, comparative study, to evaluate the safety and efficacy of Ceftaroline versus Ceftriaxone with adjunctive Clarithromycine, in the treatment of adult subjects with community acquired pneumonia. Sponsored by Cerexa 15. ASBI 307 A Phase 2b, Multicenter, Randomized, , Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SUN 11031 for Injection Administered Subcutaneously Twice Daily for 12 Weeks to Subjects Having Cachexia Associated with COPD, finalisation date: Aprilie 2009. 16. CNVA 237A2304 A study to assess the safety, tolerability and efficacy of NVA237 versus placebo in patients with moderate-to-severe COPD. Ongoing 2010 17. M/273FO/23 COPD Randomized Study Phase IIb - Principal investigator, Finalisation date: Septembrie 2008. 18. OC 000459/012/08 Dose finding study in patients with mild to moderate persistent asthma: a parallel group, randomised, placebo controlled, double blind assessment of oral OC000459 dosed at three dose schedules for twelve weeks. Principal investigator Ongoing 2010. 19. CP199 – A phase 2a, randomized, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of CAT-354, a recombinant human monoclonal antibody directed against IL-13, on asthma control in adults with uncontrolled, moderate-to-severe, persistent asthma, sub investigator ongoing 2010. Conducător diplomă 1. Aspecte clinico-imagistice în sarcoidoză, Ana Maria Cincă, 2010 2. Valoarea dozarii oxidului nitric exhalat in astmul bronsic. - Galca Estera, 2008 3. Aspecte clinico-etiologice in pneumotorax. Stefan Frent, 2004 4. Analiza cazurilor de tuberculoza pulmonara cronica apartinand la doua judete diferite: Mehedinti si Timis. - Mateescu Madalin 2000 5. Calitatea vieţii şi adaptarea bolnavului suferind de astm bronsic. Furdi Adina., 2005. Conducător doctorat i. Teze ale candidaţilor – susţinute 1. Camelia Pescaru 25.06.2010

  • 4

    Analiza siguranței medicației combinate (corticosteroizi inhalatori și bronhodilatatoare de lungă durată) la bolnavi care asociază sindroame obstructive bronșice cronice (astm bronșic sau BPOC) cu patologie cardiovasculară. 2. Nicoleta Bertici 22.10.2010 Impactul programelor de reabilitare pulmonară asupra disfuncției muscular la pacienții cu bronhopneumopatie obstructivă cronică. 3. Monica Marc 22.10.2010 Interelații între sindromul de apnee în somn și sindromul metabolic. 4. Adriana Socaci 14.01.2011 Analiza relațiilor dintre tuberculoză și diabetul zaharat. 5. Someșan Alexandru 02.12.2013 Modelarea compoziției corporale în BPOC consecutiv reabilitării corporale. 6. Stoia Djeska Irina Ionela 24.01.2014 Fibroza pulmonara de origine necunsocuta: Implicatii diagnostice si prognostice ale profilului molecular si computer tomografic 7.

Click here to load reader

Reader Image
Embed Size (px)
Recommended